

Nahid Tayebi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2877445/nahid-tayebi-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20
papers

556
citations

10
h-index

21
g-index

21
ext. papers

777
ext. citations

6.4
avg, IF

3.3
L-index

#	Paper	IF	Citations
20	A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. <i>JAMA Neurology</i> , 2013 , 70, 727-35	17.2	285
19	Lysosomal integral membrane protein-2: a new player in lysosome-related pathology. <i>Molecular Genetics and Metabolism</i> , 2014 , 111, 84-91	3.7	46
18	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021 , 53, 294-303	36.3	31
17	Exploring genetic modifiers of Gaucher disease: The next horizon. <i>Human Mutation</i> , 2018 , 39, 1739-1751	4.7	28
16	The role of epigenetics in lysosomal storage disorders: Uncharted territory. <i>Molecular Genetics and Metabolism</i> , 2017 , 122, 10-18	3.7	26
15	C-terminal β -synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease. <i>Journal of Biological Chemistry</i> , 2019 , 294, 9973-9984	5.4	23
14	Clinical course and prognosis in patients with Gaucher disease and parkinsonism. <i>Neurology: Genetics</i> , 2016 , 2, e57	3.8	23
13	Glucocerebrosidase haploinsufficiency in A53T β -synuclein mice impacts disease onset and course. <i>Molecular Genetics and Metabolism</i> , 2017 , 122, 198-208	3.7	18
12	ACE phenotyping in Gaucher disease. <i>Molecular Genetics and Metabolism</i> , 2018 , 123, 501-510	3.7	16
11	A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease. <i>DMM Disease Models and Mechanisms</i> , 2016 , 9, 769-78	4.1	14
10	Variation in cognitive function over time in Gaucher disease type 3. <i>Neurology</i> , 2019 , 93, e2272-e2283	6.5	10
9	The natural history of type 2 Gaucher disease in the 21st century: A retrospective study. <i>Neurology</i> , 2020 , 95, e2119-e2130	6.5	8
8	Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?. <i>Trends in Neurosciences</i> , 2019 , 42, 631-643	13.3	6
7	Clinical evaluation of sibling pairs with gaucher disease discordant for parkinsonism. <i>Movement Disorders</i> , 2020 , 35, 359-365	7	6
6	Type 2 Gaucher disease in an infant despite a normal maternal glucocerebrosidase gene. <i>American Journal of Medical Genetics, Part A</i> , 2017 , 173, 3211-3215	2.5	4
5	A novel alteration in metaxin 1, F202L, is associated with N370S in Gaucher disease. <i>Journal of Human Genetics</i> , 2004 , 49, 220-222	4.3	4
4	EEG abnormalities in patients with chronic neuronopathic Gaucher disease: A retrospective review. <i>Molecular Genetics and Metabolism</i> , 2020 , 131, 358-363	3.7	4

3	No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance.. <i>Movement Disorders</i> , 2022 ,	7	2
2	Next-Generation Sequencing Analysis of : The Challenge of Detecting Complex Recombinant Alleles. <i>Frontiers in Genetics</i> , 2021 , 12, 684067	4-5	2
1	Localization of Non-Factor VIII Sequence Involved in the Factor VIII Gene Inversion in Hemophilia A Dogs.. <i>Blood</i> , 2007 , 110, 1146-1146	2.2	